Document 1079
 DOCN  M94A1079
 TI    Restorani(R) in HIV-positive subjects.
 DT    9412
 AU    Banik UK; Bioscan Cont. Inc., Ste-Eustache, QC.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(2):213 (abstract no. PB0866). Unique
       Identifier : AIDSLINE ICA10/94371496
 AB    Restorani has been approved by the Health Protection Branch (HPB),
       Canada as an over-the-counter (OTC) product as a remedy for
       gastrointestinal gas and resulting colic. However, the active
       ingredient(s) of Restorani cover a wide spectra of symptoms and ailments
       including diarrhea, dysentry, gripping, ulcers, flatulence, loss of
       appetite, loss of weight, influenza, malaria, itching, cough, fever,
       enlarged glands, debility, etc. Interestingly, these are almost the same
       symptoms and ailments that occur as secondary infections in patients
       infected with HIV. Restorani, if given to asymptomatic and symptomatic
       AIDS subjects, may relieve the symptoms and ailments of secondary
       inections, and may also enhance the immune system in immunodeficient
       (ID) and HIV-Positive subjects. Restorani may be offered to ID and
       HIV-Positive subjects, since it has already been known to be a very safe
       and effective product and does not have any side effects whatsoever. The
       FDA, USA; HPB Canada; and the WHO, Geneva, Switzerland authorities are
       of the opinion that Restorani could be offered to HIV-Positive subjects
       with appropriate arrangements. The beneficial effects of the active
       principle(s) of Restorani in humans have been known for a long time. The
       time has now come to find out the efficacy of the active principle(s) of
       Restorani in HIV-Positive subjects either alone or in combination with
       other anti-AIDS drugs.
 DE    AIDS-Related Opportunistic Infections/THERAPY  Human  HIV
       Seropositivity/COMPLICATIONS/IMMUNOLOGY/*THERAPY  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).